ReviewCurrent opinion in immunology2013
T cell recognition of beryllium.
Review in Current opinion in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Identification of multiple public TCR repertoires in chronic beryllium disease.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Interleukin-1 signaling and CD4Frontiers in immunology · 2025Article
- Multisystemic Beryllium Disease: An Exceptional Case Revealed by a Urinary Tract Granulomatosis.International journal of molecular sciences · 2024Article
- Characterization of the Class I MHC Peptidome Resulting From DNCB Exposure of HaCaT Cells.Toxicological sciences : an official journal of the Society of Toxicology · 2021Article
- Involvement of Dendritic Cells and Th17 Cells in Induced Tertiary Lymphoid Structures in a Chronic Beryllium Disease Mouse Model.Mediators of inflammation · 2021Article
- The Many Faces of CD4International journal of molecular sciences · 2020Review
- Metals and molecular carcinogenesis.Carcinogenesis · 2020Review
- Metals and Mechanisms of Carcinogenesis.Annual review of pharmacology and toxicology · 2019Review
- Research to Practice Implications of High-Risk Genotypes for Beryllium Sensitization and Disease.Journal of occupational and environmental medicine · 2016Article
- Genome-wide association study of neocortical Lewy-related pathology.Annals of clinical and translational neurology · 2015Article
- The elements of life and medicines.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2015Article
- Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity.Cell · 2014Article
- Molecules in medicine mini review: the αβ T cell receptor.Journal of molecular medicine (Berlin, Germany) · 2014Review
- Chronic Beryllium Disease: revealing the role of beryllium ion and small peptides binding to HLA-DP2.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic beryllium disease (CBD) is a granulomatous lung disorder caused by a hypersensitivity to beryllium and characterized by the accumulation of beryllium-specific CD4(+) T cells in the lung. Genetic susceptibility to beryllium-induced disease is strongly associated with HLA-DP alleles possessing a glutamic acid at the 69th position of the β-chain (βGlu69). The structure of HLA-DP2, the most prevalent βGlu69-containing molecule, revealed a unique solvent-exposed acidic pocket that includes βGlu69 and represents the putative beryllium-binding site. The delineation of mimotopes and endogenous self-peptides that complete the αβTCR ligand for beryllium-specific CD4(+) T cells suggests a unique role of these peptides in metal ion coordination and the generation of altered self-peptides, blurring the distinction between hypersensitivity and autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.